Key result
Intracoronary phosphocreatine and succinic acid after primary PCI in 7 STEMI patients showed no definite increase in myocardial contractility or left ventricular ejection fraction.
Why the study?
To evaluate the cardioprotective effects of combined intracoronary phosphocreatine and succinic acid administration after primary PCI in patients presenting within 12 hours of STEMI symptom onset.
Does combined intracoronary phosphocreatine and succinic acid administration after primary PCI improve outcomes in patients with STEMI?
Observational (n=7)
Does combined intracoronary phosphocreatine and succinic acid administration after primary PCI improve outcomes in patients with STEMI?
Answers are grounded in this paper and cite their sources.
In a small case series of STEMI patients, combined intracoronary phosphocreatine and succinic acid after primary PCI did not show evidence of a definite increase in myocardial contractility.
Aim To evaluate cardioprotective effects of combined intracoronary phosphocreatine and succinic acid administration after primary percutaneous coronary intervention (PCI) in patients with ST elevation acute coronary syndrome who were present within 12 hours of symptom onset. Methods Seven patients with STEMI presenting within 12 hours of onset of symptoms and thrombotic occlusion of the left anterior descending artery were included in the study. Evaluation of efficiency and safety was performed with the recording of major adverse cardiac events, evaluation of the procedure success, and the rate of composite endpoints. Results Six (85.7%) patients after primary PCI showed TIMI grade 3 flow on control coronary angiography. None complications had been reported after intracoronary administration of phosphocreatine and succinic acid. Acquired left ventricular aneurysms were found in two patients in the in-hospital period. One patient was readmitted with acute coronary syndrome without ST-segment elevation. Coronary angiography reported restenosis of the previously implanted stent. No definite increase in the left ventricular ejection fraction had been found in the in-hospital and long-term period. Conclusion There were no evidences on definite increase in myocardial contractility. The obtained results might partially be explained by the median symptom-to-balloon time over 400 minutes.
No takes yet. Share an insight, caveat, or question.
Верещагин et al. (2019) conducted an observational in ST elevation acute coronary syndrome (STEMI) (n=7). Combined intracoronary phosphocreatine and succinic acid was evaluated on Major adverse cardiac events, procedure success, and rate of composite endpoints. Intracoronary phosphocreatine and succinic acid after primary PCI in 7 STEMI patients showed no definite increase in myocardial contractility or left ventricular ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: